{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.30","upperLimit":"27.93","value":"14.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"title":"Diabetic"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.19","upperLimit":"36.02","value":"19.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Pre-diabetic"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"33.63","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"Non-diabetic"}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"}],"units":"Participants"}],"description":"Percentage of participants who achieved biochemical control defined as GH \\<1μg/L and IGF-1 \\<ULN at week 36, overall by baseline diabetic status.","dispersionType":"95% Confidence Interval","groups":[{"description":"This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.","id":"OG000","title":"Pasireotide LAR Overall"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS) comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.","reportingStatus":"POSTED","timeFrame":"Week 36","title":"Core Phase: Percentage of Participants With Mean GH < 1 g/L and IGF-1 < ULN at Week 36 Overall by Baseline Diabetic Status","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}